CNI vs RTX

CNI presents a stable financial profile with a Piotroski F-Score of 4/9 and an absent Altman Z-Score, indicating a 'stable' but not 'strong' health trajectory. While the company boasts exceptional operating margins (42.41%) and a strong ROE (22.15%), it is currently trading at a significant premium to its Graham Number ($56.63), though it remains below its growth-based intrinsic value ($133.51). The disconnect between sluggish revenue growth (2.4%) and a high PEG ratio (2.52) suggests the stock may be overvalued relative to its current growth rate. Overall, CNI is a high-quality industrial compounder currently facing valuation headwinds and mediocre short-term financial momentum.

RTX exhibits stable financial health with a Piotroski F-Score of 5/9, yet it is trading at a severe premium compared to its Graham Number ($73.73) and Intrinsic Value ($96.67). While the company boasts an exceptional track record of earnings beats over 25 quarters and solid revenue growth, the valuation is stretched with a PEG ratio of 2.75. This fundamental overvaluation is compounded by bearish insider sentiment and a weak technical trend, suggesting that while the business is strong, the stock price is currently decoupled from its deterministic value.